The women were seropositive for HIV respond well to Gardasil human papillomavirus (HPV) vaccine, offering them protection against cervical cancer, according to a study published inApril 14 electronic edition ofClinical Infectious Diseases. Related recent research has found that both Gardasil and Cervarix are effective in people with HIV. HPV-high risk HPV-more commonly HPV-16 and HPV-18 - can cause cervical, anal, and other types of cancer. Most people are infected with HPV soon after they become sexually active, and the Centers for Disease Control and Prevention (CDC) recommends HPV vaccination for girls age 11-26 and boys age 11-21. Studies have shown that people living with HIV, especially those with compromised immune function, are more likely to be infected with various types of HPV and are less likely to eliminate the virus. Erna Milunka Kojic, Susan Cu-Uvin and colleagues from Brown University conducted a study of women with HIV in the US, Brazil, and South Africa to determine the safety and immunogenicity - or the ability to stimulate an immune response - of the Gardasil vaccine. HPV quadrivalent designed to protect against HPV types 6, 11, 16 and 18 (types 6 and 11 cause genital warts). The Group AIDS Clinical Trials investigated 5240 individuals, which included 319 HIV-positive women who were stratified by age 13-45 and T-CD4 cell counts. > 350 cells / mm3, 200-350 cells / mm3Or<200 cells/ Mm3. Most (56%) were black, 31% were Hispanics or Latinos, 11% were white and the average age was 36 years. The median CD4 count was 310 cells / mm3- Indicating the need for anti-retroviral therapy (ART) - but only 40% had detectable HIV viral load. Results
- At baseline, 4% of the participants were infected with 4 all HPV types covered by the vaccine.
- In 28 weeks after immunization, seroconversion rates - or the development of protective antibodies against HPV types 6, 11, 16 and 18, among women not already infected with the virus of each type were:
- At all levels of CD4 cells, the response was better for HPV types 6, 11 and 16 compared with 18 type.
- And lower cell count CD4 high viral load (> 10.000 copies / mL) was also associated with a poor response to the vaccine.
- The vaccine was generally well tolerated and no safety issues were identified.